Results 41 to 50 of about 109,700 (295)

Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers. [PDF]

Clin Drug Investig
Matsushima N, Shibata S, Leu JH, Vermeulen A, Duffner J, Ling LE, Schwartz LB, Harigae H.   +7 more
europepmc   +3 more sources

Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery [PDF]

Science Translational Medicine, 2013
Nanoparticles are poised to have a tremendous impact on the treatment of many diseases, but their broad application is limited because currently they can only be administered by parenteral methods.
Alexis, Frank, Blumberg, Richard S., Farokhzad, Omid C., Karnik, Rohit, Kuo, Timothy T., Langer, Robert, Levy-Nissenbaum, Etgar, Pridgen, Eric M.   +7 more
core   +6 more sources

Structure of the human astrovirus capsid spike in complex with the neonatal Fc receptor. [PDF]

Nat Commun
Lentz A, Lanning S, Iranpur KR, Ricemeyer L, Arias CF, DuBois RM.   +5 more
europepmc   +3 more sources

Dose Optimization of rhIL-7-hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor-Mediated Recycling-Based and Target-Mediated Drug Disposition Pharmacokinetic Model. [PDF]

Clin Transl Sci
Jeon HS, Lee SW, Jung W, Jung H, Choi D, Byun MS, Yun HY, Lee S, Kim A, Chae JW, Lee H.   +10 more
europepmc   +3 more sources

Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. [PDF]

Bioact Mater, 2022
Martins JP, Figueiredo P, Wang S, Espo E, Celi E, Martins B, Kemell M, Moslova K, Mäkilä E, Salonen J, Kostiainen MA, Celia C, Cerullo V, Viitala T, Sarmento B, Hirvonen J, Santos HA.   +16 more
europepmc   +2 more sources

Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus [PDF]

Journal of Investigative Dermatology, 2021
Victoria P. Werth, Donna A. Culton, Josef Symon S. Concha, James S. Graydon, Laurence Blumberg, Joyce Okawa, Michał Pyzik, Richard S. Blumberg, Russell P. Hall   +8 more
openalex   +2 more sources

Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A. [PDF]

Protein Sci
Kato A, Toshima A, Takekawa G, Miyagi H, Kubota A, Hori S, Uemura Y, Niwa R.   +7 more
europepmc   +3 more sources

Research progress on neonatal Fc receptor and its application. [PDF]

Zhejiang Da Xue Xue Bao Yi Xue Ban, 2021
Neonatal Fc receptor (FcRn) is a specific receptor for immunoglobulin G (IgG) and albumin, which binds to them in a pH-dependent manner and prevents them from lysosomal degradation to keep a long plasma half-life. In addition, FcRn plays an important role in transmembrane transport of IgG and albumin and in antigen presentation. In autoimmune diseases,
Hu M, Wei S, Zhou W, Wang P.
europepmc   +4 more sources

Neonatal Fc Receptor: From Immunity to Therapeutics [PDF]

Journal of Clinical Immunology, 2010
The neonatal Fc receptor (FcRn), also known as the Brambell receptor and encoded by Fcgrt, is a MHC class I like molecule that functions to protect IgG and albumin from catabolism, mediates transport of IgG across epithelial cells, and is involved in antigen presentation by professional antigen presenting cells. Its function is evident in early life in
Kuo, Timothy Ting-Chang, Baker, Kristi, Yoshida, Masaru, Qiao, Shuo-Wang, Aveson, Victoria G., Lencer, Wayne, Blumberg, Richard   +6 more
openaire   +3 more sources

Neonatal Fc receptor and IgG-based therapeutics [PDF]

mAbs, 2011
The majority of potent new biologics today are IgG-based molecules that have demonstrated tissue-targeting specificity with favorable clinical response. Several factors determine the efficacy of these products, including target specificity, serum half-life and effector functions via complement-dependent cytotoxicity, antibody-dependent cell-mediated ...
Timothy T, Kuo, Victoria G, Aveson
openaire   +2 more sources